Table 1.
Baseline characteristics of the patients included in this study based on previously published data from the RCT conducted by Hvas et al. 21
| Parameter | Overall (n = 64) |
|---|---|
| Age (years), median (range) | 68 (21–92) |
| Women, n (%) | 44 (69) |
| Charlson comorbidity index score, median (range) | 1 (0–7) |
| WHO performance score, median (range) | 1 (0–4) |
| Previous CDIs (n), median (range) | 4 (2–10) |
| Previous CDI treatments, n (%) | |
| Metronidazole | 48 (75) |
| Vancomycin | 64 (100) |
| Fidaxomicin | < 5 (<10) |
| Ribotype 027, n (%) | 0 (0) |
| Hospital admission at inclusion, n (%) | 6 (10) |
| Intensive care admission < 1 mo before inclusion, n (%) | 0 (0) |
| Liquid stools per 24 h (n), median (range) | 6 (3–31) |
| Duration of symptoms during the current CDI (days), median (range) | 13 (1–152) |
| Duration since onset of the first CDI (days), median (range) | 136 (25–963) |
CDI, Clostridioides difficile infection; RCT, randomised controlled trial; WHO, World Health Organization.